{"pmid":32249847,"title":"In the eye of the COVID-19 cytokine storm.","text":["In the eye of the COVID-19 cytokine storm.","Nat Rev Immunol","Vaninov, Natalie","32249847"],"journal":"Nat Rev Immunol","authors":["Vaninov, Natalie"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32249847","week":"202015|Apr 06 - Apr 12","doi":"10.1038/s41577-020-0305-6","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663352136271921152,"score":7.6679378,"similar":[{"pmid":32238976,"title":"Cytokine storms in COVID-19 cases?","text":["Cytokine storms in COVID-19 cases?","Tidsskr Nor Laegeforen","Tveito, Kari","32238976"],"journal":"Tidsskr Nor Laegeforen","authors":["Tveito, Kari"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32238976","week":"202014|Mar 30 - Apr 05","doi":"10.4045/tidsskr.20.0239","link_comment_for":"32192578","source":"PubMed","weight":0,"_version_":1663352135464517634,"score":70.48678},{"pmid":32192578,"title":"COVID-19: consider cytokine storm syndromes and immunosuppression.","text":["COVID-19: consider cytokine storm syndromes and immunosuppression.","Lancet","Mehta, Puja","McAuley, Daniel F","Brown, Michael","Sanchez, Emilie","Tattersall, Rachel S","Manson, Jessica J","32192578"],"journal":"Lancet","authors":["Mehta, Puja","McAuley, Daniel F","Brown, Michael","Sanchez, Emilie","Tattersall, Rachel S","Manson, Jessica J"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32192578","week":"202012|Mar 16 - Mar 22","doi":"10.1016/S0140-6736(20)30628-0","link_comment_in":"32238976","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352133527797762,"score":62.80583},{"pmid":32205092,"title":"TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.","text":["TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.","COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles.","J Microbiol Immunol Infect","Wu, Dandan","Yang, Xuexian O","32205092"],"abstract":["COVID-19 emerges as a pandemic disease with high mortality. Development of effective prevention and treatment is an urgent need. We reviewed TH17 responses in patients with SARS-CoV-2 and proposed an FDA approved JAK2 inhibitor Fedratinib for reducing mortality of patients with TH17 type immune profiles."],"journal":"J Microbiol Immunol Infect","authors":["Wu, Dandan","Yang, Xuexian O"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32205092","week":"202013|Mar 23 - Mar 29","doi":"10.1016/j.jmii.2020.03.005","keywords":["COVID-19","Cytokine storm","JAK2 inhibitor","SARS-CoV-2","TH17"],"source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["Fedratinib"],"_version_":1663352133701861377,"score":51.567257},{"pmid":32114747,"title":"[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].","text":["[Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies].","Corona Virus Disease 2019 (COVID-19) has seriously affected the treatment of patients and social stability. In the later stage of disease, some COVID-19 patients may develop into acute respiratory distress syndrome or even multiple organ failure. However, one of the most important mechanism underlying the deterioration of disease is cytokine storm. At present, some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. This article reviews the influences of cytokine storm syndrome on the COVID-19 and the corresponding immunotherapies to resist cytokine storm.","Zhonghua Shao Shang Za Zhi","Chen, C","Zhang, X R","Ju, Z Y","He, W F","32114747"],"abstract":["Corona Virus Disease 2019 (COVID-19) has seriously affected the treatment of patients and social stability. In the later stage of disease, some COVID-19 patients may develop into acute respiratory distress syndrome or even multiple organ failure. However, one of the most important mechanism underlying the deterioration of disease is cytokine storm. At present, some therapies such as interleukin-6 antibody blocker, stem cell therapy, and transfusion of convalescent plasma have been applied to counteract the cytokine storm and have made some progress. This article reviews the influences of cytokine storm syndrome on the COVID-19 and the corresponding immunotherapies to resist cytokine storm."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Chen, C","Zhang, X R","Ju, Z Y","He, W F"],"date":"2020-03-03T11:00:00Z","year":2020,"_id":"32114747","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn501120-20200224-00088","keywords":["Corona Virus Disease 2019","Cytokine storm","Cytokines","Immune system","Immunotherapy"],"source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352134347784193,"score":46.972942},{"pmid":32247038,"pmcid":"PMC7118642","title":"Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19.","text":["Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19.","Clin Immunol","Ma, Jie","Xia, Peng","Zhou, Yangzhong","Liu, Zhengyin","Zhou, Xiang","Wang, Jinglan","Li, Taisheng","Yan, Xiaowei","Chen, Limeng","Zhang, Shuyang","Qin, Yan","Li, Xuemei","32247038"],"journal":"Clin Immunol","authors":["Ma, Jie","Xia, Peng","Zhou, Yangzhong","Liu, Zhengyin","Zhou, Xiang","Wang, Jinglan","Li, Taisheng","Yan, Xiaowei","Chen, Limeng","Zhang, Shuyang","Qin, Yan","Li, Xuemei"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32247038","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.clim.2020.108408","keywords":["Blood purification","Critically ill COVID-19","Cytokine storm","IL-6","Plasma exchange"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135871365120,"score":45.465504}]}